The Saxenda vs Wegovy question comes up almost every week now, and it’s a fair one. Both are FDA-approved injectable GLP-1 medications for chronic weight management. Both come from the same manufacturer, Novo Nordisk. Both are taken by injection. So why does one seem to dominate the conversation while the other quietly does its job?
The short answer: they’re not the same drug, and the weight loss numbers aren’t close. But that doesn’t automatically mean Wegovy is the right pick for every patient.
What patients usually want to know is which one will actually move the scale, what the side effects feel like in real life, and whether the cost difference is worth it. That’s what we’ll work through here, with the data from the actual FDA labeling and the published trials.
Saxenda vs Wegovy: The Basic Difference
Saxenda is liraglutide, a daily GLP-1 receptor agonist. Wegovy is semaglutide, a weekly GLP-1 receptor agonist. Both mimic a gut hormone that slows stomach emptying, reduces appetite, and helps the brain register fullness earlier in a meal.
Liraglutide came first. The FDA approved it for weight management in 2014 at the 3.0 mg dose. Semaglutide for weight loss came along in 2021, building on the same mechanism but with a longer half-life and a stronger appetite-suppressing effect at the doses studied.
That’s the key structural difference in Saxenda vs Wegovy. One you inject every day. The other, once a week. If you’re someone who’d rather not think about a daily shot, that alone matters.
If you want a deeper background on how this drug class works in the body, we walk through it in this patient guide to GLP-1 medications.
Weight Loss Results: What the Trials Actually Showed
This is where Saxenda vs Wegovy stops being a close race.
In the SCALE trial, patients on Saxenda 3.0 mg lost about 8% of body weight on average over 56 weeks, compared to roughly 2.6% on placebo. Solid, but modest.
In the STEP 1 trial published in NEJM in 2021, patients on Wegovy 2.4 mg lost about 14.9% of body weight at 68 weeks, versus 2.4% on placebo. Nearly double the response.
A head-to-head trial (STEP 8) compared them directly. Wegovy produced about 15.8% weight loss; Saxenda came in around 6.4%. Same patient population, same diet and activity counseling.
So on average, Wegovy outperforms Saxenda by a meaningful margin. But "on average" hides a lot. Some patients respond beautifully to liraglutide and tolerate it better. Others can’t get semaglutide because of supply, insurance denials, or side effects.
Side Effects: What Patients Actually Report
Both drugs share the same GLP-1 side effect profile, and the list looks similar on paper:
- Nausea, especially during dose escalation
- Constipation or diarrhea
- Abdominal pain or bloating
- Fatigue and headache in the first few weeks
- Injection site reactions
- Rare but serious: pancreatitis, gallbladder problems, kidney injury from dehydration
In practice, the nausea on Wegovy tends to be more intense at the top doses, partly because the drug stays in the system longer. With Saxenda, the daily injection means side effects come and go on a shorter cycle, which some patients actually prefer because a bad day doesn’t last a week.
Both drugs carry an FDA boxed warning for the risk of medullary thyroid carcinoma based on rodent studies, and neither should be used in patients with a personal or family history of medullary thyroid cancer or MEN 2 syndrome. The Mayo Clinic’s liraglutide overview has a good plain-language rundown of who should avoid these drugs entirely.
Cost, Insurance, and Access in 2026
List prices in the US are roughly comparable, north of $1,300 per month for both brands without insurance. That’s the sticker shock part.
What actually shapes the Saxenda vs Wegovy choice for most patients is coverage. Some commercial plans cover one but not the other. Medicare still doesn’t cover either drug for weight loss alone, though that’s an active policy debate. Manufacturer savings cards can bring commercially insured patients down to around $0 to $25 per month, but eligibility is narrow.
If cost is the deciding factor, it’s worth comparing the GLP-1 landscape more broadly. We break down how semaglutide stacks up against the newer tirzepatide in this comparison of Wegovy and Zepbound’s active ingredients, which is useful context if your prescriber is weighing several options. Compare current pricing and availability on GLP-1 options at edrugstore.com before you commit to a year of therapy.
When Saxenda Might Actually Be the Better Pick
Wegovy isn’t automatically the winner in Saxenda vs Wegovy, even with the better weight loss numbers. A few scenarios where liraglutide makes sense:
- You’ve had severe GI side effects on semaglutide. A shorter-acting drug clears faster if something goes wrong.
- Your insurance covers Saxenda but not Wegovy. This is more common than you’d think.
- You want more dosing flexibility. Daily dosing lets you pause or adjust faster.
- You’re planning pregnancy in the near future. Neither drug is recommended in pregnancy, but liraglutide’s shorter washout is sometimes preferred when timing matters.
For most patients without those specific issues, the data favors Wegovy.
How to Decide With Your Prescriber
The honest answer on Saxenda vs Wegovy is that the right pick depends on your starting weight, your other conditions (especially type 2 diabetes, where related drugs like Ozempic come into play), what your insurance will pay for, and how your gut tolerates the class.
Some questions worth bringing to the appointment:
- What’s my realistic weight loss goal over 12 months?
- Which drug does my plan cover, and at what tier?
- Should we try the lower-cost option first and switch if results stall?
- What’s the plan if I can’t tolerate the side effects?
If you’re newer to this class and want to understand the broader category, our overview of GLP-1 versus GLP-1 Plus formulations is a helpful primer on what’s actually inside these pens.
The Bottom Line on Saxenda vs Wegovy
For most patients, the Saxenda vs Wegovy decision comes down to access, tolerance, and dosing preference, with Wegovy holding the edge on raw weight loss data. Saxenda still has a real role, especially when insurance, side effects, or daily dosing preference tip the scale. Neither is a substitute for the food, sleep, and movement changes that make the results stick after you stop the drug.
Talk to your prescriber about which GLP-1 fits your medical history, and ask your pharmacist to check your formulary before you start. The right drug is the one you can actually access, afford, and tolerate long enough to see results.
This article is for informational purposes only and is not medical advice. Always consult a licensed pharmacist or physician before starting, stopping, or changing any medication.
References
- FDA approval announcement for Saxenda (liraglutide 3.0 mg), original regulatory approval and indication.
- STEP 1 trial, New England Journal of Medicine (2021), pivotal semaglutide 2.4 mg weight loss data.
- Mayo Clinic: Liraglutide subcutaneous route, patient-facing safety and side effect summary.
Dr Steven Schlosser
Dr. Schlosser graduated from Lafayette College Phi Beta Kappa and attended Georgetown Medical School. He had 4 years of medical residency training at Tufts University in Boston in both Gynecology and Internal Medicine. He has had a spotless medical career for the past 40+ years and is Board Certified. Learn More